







Praziquantel, praziquantel plus mefloquine and praziquantel plus mefloquine-artesunate in the treatment of schistosomiasis

Submission date 06/05/2010	Recruitment status No longer recruiting	 Prospectively registered
Registration date 27/05/2010	Overall study status Completed	 Protocol not yet added
Last Edited 17/12/2015	Condition category Infections and Infestations	 SAP not yet added
		 Results added
		 Raw data not yet added
		 Study completed

Plain English Summary

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Jennifer Keiser

Contact details

Socinstr. 57
Basel
Switzerland
4051

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Protocol/serial number

N/A

Study information

Scientific Title

Praziquantel, praziquantel plus mefloquine and praziquantel plus mefloquine-artesunate in the treatment of infections with *Schistosoma* spp. in Cote d'Ivoire

Acronym

PZQM-Q-Schisto

Study hypothesis

Combinations of mefloquine and mefloquine-artesunate plus praziquantel show a better efficacy against *Schistosoma* spp. infections in school-aged children in Africa.

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Ethikkommission beider Basel EKBB, Switzerland, 21/08/2009, ref: 70/08
2. Ministry of Health Cote d'Ivoire, 03/04/2010

Study design

Randomised exploratory open-label active-controlled parallel-group phase II trial

Primary study design

Interventional

Secondary study design

Randomised parallel trial

Study setting(s)

Other

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Condition

Infection with *Schistosoma* spp.

Interventions

Drug administration, namely:

1. Praziquantel (1 x 40 mg/kg)
2. Mefloquine (1 x 25 mg/kg) plus praziquantel (1 x 40 mg/kg) on the next day
3. Mefloquine-artesunate combination (300/750 mg in three divided doses within 3 days) plus praziquantel (1 x 40 mg/kg) on day 4

The duration of treatment is dependant on the drug regimen (i.e., 1 - 4 days). The total duration of follow-up is 3 - 5 days.

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Praziquantel, mefloquine, mefloquine-artesunate

Primary outcome measure

Cure rate and egg reduction rate, measured at 21 - 28 days and 2 - 3 months post-treatment by multiple stool and urine sampling (Kato Katz method, urine filtration and ether concentration technique)

Secondary outcome measures

Adverse events. Patients will be monitored for 3 hours post-treatment and once daily during treatment and for 3 days after the last dose. Details of adverse events will be recorded by the study physician during the trial, including variables describing their incidence, onset, cessation, duration, intensity, frequency, seriousness and causality.

Overall study start date

01/07/2011

Overall study end date

30/09/2011

Eligibility**Participant inclusion criteria**

1. Patients (male and female school children older than 8 years) infected with *Schistosoma mansoni* and *S. haematobium*, as assessed by the presence of eggs in the urine or stool
2. Weight of patient greater than 25 kg
3. Able and willing to be examined by a study physician at the beginning of the study and at the end of study (3 weeks post-treatment and 2 - 3 months post-treatment)
4. Able and willing to provide multiple stool and urine samples at the beginning and end of study
5. Absence of major systemic illnesses, as assessed by the medical doctor, upon initial clinical assessment
6. Absence of psychiatric and neurological disorders
7. No known or reported hypersensitivity to mefloquine, praziquantel and/or artesunate
8. No known or reported history of chronic illness as cancer, diabetes, chronic heart, liver or renal disease
9. Signed written informed consent sheet
10. For females aged 12 years and above, not pregnant in the first trimester, as assessed by a pregnancy test, upon initial clinical assessment

Participant type(s)

Patient

Age group

Child

Lower age limit

8 Years

Sex

Both

Target number of participants

150 (60 at time of registration)

Participant exclusion criteria

1. Pregnancy first trimester
2. Presence of any abnormal medical condition, judged by the study physician
3. History of acute or severe chronic disease
4. Known or reported psychiatric or neurological disorders
5. Use of antimalarial or anthelmintic drug within the past month
6. Attending other clinical trials during the study

Recruitment start date

01/07/2011

Recruitment end date

30/09/2011

Locations**Countries of recruitment**

Cote d'Ivoire

Switzerland

Study participating centre

Socinstr. 57

Basel

Switzerland

4051

Sponsor information**Organisation**

Swiss Tropical and Public Health Institute (Switzerland)

Sponsor details

Socinstr. 57
Basel
Switzerland
4051

Sponsor type

Research organisation

Website

<http://www.swisstph.ch/>

ROR

<https://ror.org/03adhka07>

Funder(s)

Funder type

Research organisation

Funder Name

Swiss National Science Foundation (Fonds National Suisse de la Recherche Scientifique [SNSF])
(Switzerland)

Alternative Name(s)

Schweizerischer Nationalfonds, Swiss National Science Foundation, Fonds National Suisse de la Recherche Scientifique, Fondo Nazionale Svizzero per la Ricerca Scientifica, Fonds National Suisse, Fondo Nazionale Svizzero, Schweizerische Nationalfonds, SNF, SNSF, FNS

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

Switzerland

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	17/07/2014		Yes	No